Fig. 1.

Construction and characterization of ChinZIKV. a Strategy for construction of the chimeric ZIKV vaccine ChinZIKV and schematic representation of its genome. b Immunostaining of BHK-21 cells infected with ChinZIKV-, ZIKV-, or mock-infected at an MOI of 0.01 at 48 h post-infection with ZIKV patient anti-serum and JEV NS1 antibodies. Scale bar: 100 μm. c Plaque morphology of ZIKV, the recovered ChinZIKV, and ChinZIKV at passages 3 and 6 on BHK-21 cells. BHK-21 cells were infected with the indicated viruses, and plaques were developed after 96 h. d Growth curves of the recovered ChinZIKV and ChinZIKV at passage 6 in Vero cells. Vero cells were infected with the indicated viruses at an MOI of 2 and the cell supernatants were collected at the indicated times for determination of virus titers by plaque assay using BHK-21 cells. The data are representative of at least three independent experiments and error bars indicate the SD